Evommune, Inc. (EVMN)
| Market Cap | 461.76M |
| Revenue (ttm) | 10.00M +233.3% |
| Net Income | -75.99M |
| EPS | -5.36 |
| Shares Out | 36.02M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,605,573 |
| Open | 13.27 |
| Previous Close | 13.29 |
| Day's Range | 12.65 - 13.82 |
| 52-Week Range | 12.65 - 33.20 |
| Beta | n/a |
| Analysts | Buy |
| Price Target | 35.86 (+179.72%) |
| Earnings Date | Aug 7, 2026 |
About EVMN
Evommune, Inc. operates as a clinical-stage biotechnology company in the United States. The company develops therapies that target key drivers of chronic inflammatory diseases, with initial clinical development programs focusing on chronic spontaneous urticaria, atopic dermatitis, and ulcerative colitis. Its products include EVO756 for the treatment of CSU and AD; and EVO301 for the treatment of AD and UC. The company was incorporated in 2020 and is headquartered in Palo Alto, California.
Financial Performance
In 2025, Evommune's revenue was $13.00 million, an increase of 85.71% compared to the previous year's $7.00 million. Losses were -$68.87 million, 0.82% more than in 2024.
Financial StatementsAnalyst Summary
According to 10 analysts, the average rating for EVMN stock is "Buy." The 12-month stock price target is $35.86, which is an increase of 179.72% from the latest price.
News
Septerna price target lowered to $45 from $52 at Guggenheim
Guggenheim analyst Seamus Fernandez lowered the firm’s price target on Septerna (SEPN) to $45 from $52 and keeps a Buy rating on the shares after Evommune (EVMN) announced top-line results…
Evommune price target lowered to $26 from $55 at Morgan Stanley
Morgan Stanley lowered the firm’s price target on Evommune (EVMN) to $26 from $55 and keeps an Overweight rating on the shares after the failure of its lead asset, EVO756,…
Evommune downgraded to Neutral from Buy at H.C. Wainwright
H.C. Wainwright analyst Mitchell Kapoor downgraded Evommune (EVMN) to Neutral from Buy without a price target after EVO756 failed to meet the Phase 2b primary endpoint. This is “materially damaging”…
Evommune price target lowered to $28 from $53 at Clear Street
Clear Street lowered the firm’s price target on Evommune (EVMN) to $28 from $53 and keeps a Buy rating on the shares after the company announced that the Phase IIb…
Evommune downgraded to Market Perform from Outperform at William Blair
William Blair downgraded Evommune (EVMN) to Market Perform from Outperform without a price target after the company announced that the Phase IIb study of EVO756 in chronic spontaneous urticaria failed...
Evommune announces Phase 2b trial of EVO756 did not meet primary endpoint
Evommune (EVMN) announced top-line results from its randomized, double-blind, placebo controlled, dose-ranging Phase 2b trial evaluating the efficacy and safety of oral MRGPRX2 antagonist, EVO756, in ...
Evommune Announces Top-line Results from EVO756 Phase 2b Trial in Moderate-to-Severe Chronic Spontaneous Urticaria
PALO ALTO, Calif. & NEW YORK--(BUSINESS WIRE)--Evommune, Inc. (NYSE: EVMN) (the “Company” or “Evommune”), a clinical-stage biotechnology company developing innovative therapies that target key drivers...
Apogee deal gives positive readthrough to Evommune pipeline, says Clear Street
Clear Street reiterated a Buy rating and $53 price target on Evommune (EVMN), saying Abbvie’s (ABBV) proposed acquisition of Apogee (APGE) provides a positive readthrough to Evommune’s pipeline. In pa...
Evommune Transcript: AGM 2026
The meeting covered the election of two directors and ratification of the independent auditor, with both proposals approved. No shareholder questions were submitted, and voting results will be reported on Form 8-K within four business days.
Evommune price target raised to $55 from $54 at Morgan Stanley
Morgan Stanley raised the firm’s price target on Evommune (EVMN) to $55 from $54 and keeps an Overweight rating on the shares.
Evommune reports Q1 EPS (64c), consensus (71c)
“We continue to make meaningful progress across our broad chronic inflammation targeted pipeline and remain on track to deliver top-line Phase 2b data for EVO756 in CSU in June and…
Evommune Reports First Quarter 2026 Financial Results and Provides Business Highlights
PALO ALTO, Calif. & NEW YORK--(BUSINESS WIRE)--Evommune, Inc. (NYSE: EVMN) (“Evommune” or the “Company”), a clinical-stage biotechnology company developing innovative therapies that target key drivers...
Evommune Quarterly report: Q1 2026
Evommune has published its Q1 2026 quarterly earnings report on May 7, 2026.
Evommune Earnings release: Q1 2026
Evommune released its Q1 2026 earnings on May 7, 2026, summarizing the period's financial results.
Evommune Slides: Corporate presentation
Evommune has posted slides in relation to its latest quarterly earnings report, which was published on May 7, 2026.
Evommune initiated with a Buy at Stifel
Stifel initiated coverage of Evommune (EVMN) with a Buy rating and $54 price target The firm views MRGPRX2 as “an exciting target across a range of diseases with mast cell…
Evommune Proxy statement: Proxy filing
Evommune filed a proxy statement on April 21, 2026, providing details for shareholder voting and corporate governance matters.
Evommune Proxy statement: Proxy filing
Evommune filed a proxy statement on April 21, 2026, providing details for shareholder voting and corporate governance matters.
Evommune Registration statement: Registration filing
Evommune filed a registration statement on April 17, 2026, providing details about a securities offering with the SEC.
Evommune Transcript: Status update
A new phase IIb trial will evaluate EVO756, an oral MRGPRX2 antagonist, for migraine prevention, aiming to address unmet needs beyond current CGRP therapies. The program leverages strong mechanistic rationale and seeks to disrupt neuroinflammatory cycles in migraine, with top-line data expected in 2027.
Evommune assumed with an Outperform at Oppenheimer
Oppenheimer assumed coverage of Evommune (EVMN) with an Outperform rating and $50 price target The firm says investor focus is on Q2 readout in chronic spontaneous urticaria, wherein substantial unmet...
Evommune to Host KOL Webinar on April 13, 2026 Highlighting the Potential of MRGPRX2 Inhibition in Migraine
PALO ALTO, Calif. & NEW YORK--(BUSINESS WIRE)--Evommune, Inc. (NYSE: EVMN) (“Evommune” or the “Company”), a clinical-stage biotechnology company developing innovative therapies that target key drivers...
Evommune price target lowered to $50 from $65 at H.C. Wainwright
H.C. Wainwright lowered the firm’s price target on Evommune (EVMN) to $50 from $65 and keeps a Buy rating on the shares. The firm cites the company’s recent equity dilution…
Evommune initiated with a Buy at Clear Street
Clear Street initiated coverage of Evommune (EVMN) with a Buy rating and $53 price target The firm views “first-in-class” oral EVO756 offering “an attractive risk-reward” in chronic spontaneous urtica...
Evommune initiated with an Outperform at RBC Capital
RBC Capital initiated coverage of Evommune (EVMN) with an Outperform rating and $48 price target The firm says “optimized” pharmacology and development approaches for its lead agents ‘along with “prom...